Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2018-11-14 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.34 | +6,400 | 729,792 | +1% | +$14,984 | |||||
2018-11-14 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.14 | +1,000 | 3,585,094 | 0% | +$2,141 | ||||||
2018-11-15 | BOLD | Audentes Therapeutics, Inc. | Lange Louis G | Dir | S - Sale | $22.49 | -24,000 | 411,933 | -6% | -$539,760 | ||||||
| D | 2018-11-15 | SGMO | Sangamo Therapeutics, Inc | Yi Kathy | SVP, CFO | S - Sale+OE | $10.00 | -5,000 | 7,250 | -41% | -$50,000 | |||||
2018-11-14 | SGMO | Sangamo Therapeutics, Inc | Parker H Stewart | Dir | P - Purchase | $9.00 | +2,000 | 7,500 | +36% | +$18,002 | ||||||
| M | 2018-11-14 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $34.62 | -7,800 | 768,563 | -1% | -$270,052 | |||||
| M | 2018-11-13 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $18.09 | -18,334 | 2,741,809 | -1% | -$331,664 | |||||
2018-11-15 | ATRA | Atara Biotherapeutics, Inc. | Haqq Christopher | EVP, R, D, Chief Scientific Of | S - Sale | $33.81 | -775 | 305,580 | 0% | -$26,203 | ||||||
| M | 2018-11-12 | NK | Nantkwest, Inc. | Gorlin Steve | Dir | S - Sale | $2.29 | -196,280 | 321,720 | -38% | -$450,068 | |||||
2018-11-12 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale | $13.15 | -352 | 135,622 | 0% | -$4,629 | ||||||
2018-11-12 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale | $13.15 | -352 | 80,627 | 0% | -$4,629 | ||||||
2018-11-12 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Chief Business Officer | S - Sale | $13.15 | -530 | 111,576 | 0% | -$6,970 | ||||||
2018-11-12 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale | $13.15 | -113 | 62,814 | 0% | -$1,486 | ||||||
| D | 2018-11-09 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $130.59 | -1,500 | 35,495 | -4% | -$195,891 | |||||
| M | 2018-11-12 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.16 | +3,900 | 723,392 | +1% | +$8,412 | |||||
2018-11-13 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.10 | +1,000 | 3,584,094 | 0% | +$2,100 | ||||||
2018-11-12 | NBIX | Neurocrine Biosciences Inc | Pops Richard F | Dir | S - Sale | $103.30 | -4,123 | 33,636 | -11% | -$425,893 | ||||||
2018-11-08 | ONVO | Organovo Holdings, Inc. | Presnell Sharon Collins | Chief Scientific Officer | S - Sale | $1.27 | -40,000 | 292,193 | -12% | -$50,800 | ||||||
2018-11-09 | HSKA | Heska Corp | Wilson Kevin S. | CEO, Pres | S - Sale | $104.07 | -3,190 | 410,472 | -1% | -$331,992 | ||||||
| D | 2018-11-08 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale+OE | $14.09 | -229 | 62,927 | 0% | -$3,227 | |||||
| D | 2018-11-08 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale+OE | $14.09 | -218 | 80,979 | 0% | -$3,072 | |||||
| D | 2018-11-08 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale+OE | $14.09 | -409 | 135,974 | 0% | -$5,763 | |||||
| DM | 2018-11-08 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale+OE | $13.50 | -4,374 | 583,489 | -1% | -$59,043 | |||||
| D | 2018-11-08 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | SVP, Corporate Development | S - Sale+OE | $14.09 | -646 | 112,106 | -1% | -$9,102 | |||||
2018-11-07 | GNMX | Aevi Genomic Medicine, Inc. | Grano Joseph J Jr | Dir | P - Purchase | $1.16 | +68,000 | 174,847 | +64% | +$78,932 | ||||||
| D | 2018-11-08 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $110.00 | -36,295 | 135,997 | -21% | -$3,992,450 | |||||
| D | 2018-11-08 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $61.54 | -20,148 | 732,613 | -3% | -$1,239,873 | |||||
| M | 2018-11-08 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.50 | +500 | 719,492 | 0% | +$1,251 | |||||
| A | 2018-06-20 | TROV | Trovagene, Inc. | Markin Rodney S | Dir | P - Purchase | $0.85 | +41,200 | 43,085 | >999% | +$35,020 | |||||
2018-11-07 | RGNX | Regenxbio Inc. | Christmas Patrick J. | SVP, GC | S - Sale | $72.06 | -15,000 | 2,669 | -85% | -$1,080,900 | ||||||
| DM | 2018-11-07 | BCRX | Biocryst Pharmaceuticals Inc | Staab Thomas R II | SVP, CFO | S - Sale+OE | $8.12 | -14,087 | 137,383 | -9% | -$114,387 | |||||
| DM | 2018-11-07 | BCRX | Biocryst Pharmaceuticals Inc | Powell Lynne | SVP - CCO | S - Sale+OE | $8.14 | -5,580 | 8,605 | -39% | -$45,432 | |||||
| DM | 2018-11-06 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $110.13 | -38,819 | 135,997 | -22% | -$4,275,300 | |||||
| DM | 2018-11-06 | NBIX | Neurocrine Biosciences Inc | Lloyd-Smith Malcolm | Chief Regulatory Officer | S - Sale+OE | $110.01 | -9,000 | 15,318 | -37% | -$990,096 | |||||
2018-11-06 | CSBR | Champions Oncology, Inc. | Mendelson Daniel Newman | Dir | S - Sale | $13.75 | -5,000 | 57,500 | -8% | -$68,750 | ||||||
2018-11-07 | ATRA | Atara Biotherapeutics, Inc. | Marcus Joel S | Dir | S - Sale | $36.35 | -10,000 | 919,945 | -1% | -$363,500 | ||||||
| A | 2014-10-21 | ATRA | Atara Biotherapeutics, Inc. | Marcus Joel S | Dir | P - Purchase | $11.00 | +9,090 | 9,090 | New | +$99,990 | |||||
| D | 2018-11-06 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $15.39 | -50,000 | 75,163 | -40% | -$769,500 | |||||
2018-11-07 | ATRA | Atara Biotherapeutics, Inc. | Gallagher Carol Giltner | Dir | S - Sale | $36.38 | -21,374 | 88,818 | -19% | -$777,586 | ||||||
| D | 2018-11-05 | RGNX | Regenxbio Inc. | Yoo Stephen | Chief Medical Officer | S - Sale+OE | $68.28 | -20,414 | 0 | -100% | -$1,393,933 | |||||
2018-11-05 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale | $68.25 | -20,000 | 306,000 | -6% | -$1,364,902 | ||||||
| D | 2018-11-06 | SGMO | Sangamo Therapeutics, Inc | Conner Edward R. | SVP, Chief Medical Officer | S - Sale+OE | $13.73 | -5,000 | 12,125 | -29% | -$68,650 | |||||
2018-11-05 | BCDA | Biocardia, Inc. | McClung David | CFO | P - Purchase | $2.56 | +1,600 | 6,200 | +35% | +$4,102 | ||||||
| D | 2018-11-05 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $137.38 | -1,800 | 30,871 | -6% | -$247,277 | |||||
| D | 2018-11-05 | BCRX | Biocryst Pharmaceuticals Inc | Powell Lynne | SVP - CCO | S - Sale+OE | $8.00 | -100 | 8,605 | -1% | -$800 | |||||
| D | 2018-11-05 | BCRX | Biocryst Pharmaceuticals Inc | Staab Thomas R II | SVP, CFO | S - Sale+OE | $8.00 | -215 | 137,383 | 0% | -$1,720 | |||||
2018-11-02 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.52 | +400 | 718,992 | 0% | +$1,008 | ||||||
2018-11-02 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.53 | +2,000 | 3,583,094 | 0% | +$5,060 | ||||||
2018-11-05 | RGEN | Repligen Corp | Ryan Thomas F Jr | Dir | S - Sale | $65.75 | -1,763 | 3,225 | -35% | -$115,920 | ||||||
| D | 2018-11-02 | TWST | Twist Bioscience Corp | Crandell Keith | Dir, 10% | P - Purchase | $14.00 | +75,000 | 954,146 | +9% | +$1,050,000 | |||||
| D | 2018-11-02 | TWST | Twist Bioscience Corp | Arch Venture Partners Viii, LLC | 10% | P - Purchase | $14.00 | +75,000 | 954,146 | +9% | +$1,050,000 | |||||
| D | 2018-11-02 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $133.64 | -5,000 | 24,905 | -17% | -$668,216 | |||||
| D | 2018-11-02 | BCRX | Biocryst Pharmaceuticals Inc | Powell Lynne | SVP - CCO | S - Sale+OE | $8.00 | -1,000 | 8,605 | -10% | -$8,000 | |||||
| D | 2018-11-02 | BCRX | Biocryst Pharmaceuticals Inc | Staab Thomas R II | SVP, CFO | S - Sale+OE | $7.84 | -10,856 | 137,383 | -7% | -$85,090 | |||||
2018-11-05 | HEB | Hemispherx Biopharma Inc | Appelrouth Stewart | Dir | P - Purchase | $0.22 | +25,238 | 266,988 | +10% | +$5,552 | ||||||
| D | 2018-11-01 | GILD | Gilead Sciences Inc | Martin John C | Dir | S - Sale+OE | $69.55 | -50,000 | 3,017,762 | -2% | -$3,477,617 | |||||
2018-11-01 | EDIT | Editas Medicine, Inc. | Bosley Katrine | Pres, CEO | S - Sale | $26.88 | -12,000 | 1,228,966 | -1% | -$322,508 | ||||||
| DM | 2018-11-01 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale+OE | $70.20 | -73,418 | 137,283 | -35% | -$5,154,020 | |||||
2018-11-02 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale | $114.41 | -15,000 | 245,697 | -6% | -$1,716,213 | ||||||
2018-11-01 | BCRX | Biocryst Pharmaceuticals Inc | Powell Lynne | SVP - CCO | S - Sale | $7.51 | -1,544 | 8,605 | -15% | -$11,595 | ||||||
| D | 2018-11-01 | ATRA | Atara Biotherapeutics, Inc. | Newell Joe | Chief Tech. Operations Officer | S - Sale+OE | $35.00 | -1,500 | 31,858 | -4% | -$52,500 | |||||
| D | 2018-11-01 | AERI | Aerie Pharmaceuticals Inc | Kopczynski Casey C. | Chief Scientific Officer | S - Sale+OE | $53.87 | -11,000 | 128,743 | -8% | -$592,521 | |||||
2018-10-30 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.55 | +300 | 718,592 | 0% | +$765 | ||||||
| D | 2018-10-29 | RGNX | Regenxbio Inc. | Yoo Stephen | Chief Medical Officer | S - Sale+OE | $62.37 | -20,414 | 0 | -100% | -$1,273,212 | |||||
2018-10-29 | NBIX | Neurocrine Biosciences Inc | Pops Richard F | Dir | S - Sale | $107.13 | -5,500 | 37,759 | -13% | -$589,237 | ||||||
| D | 2018-10-26 | EDIT | Editas Medicine, Inc. | Hack Andrew A. F. | CFO | S - Sale+OE | $25.70 | -6,000 | 0 | -100% | -$154,200 | |||||
| M | 2018-10-25 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.36 | +3,850 | 718,292 | +1% | +$9,080 | |||||
2018-10-26 | HEB | Hemispherx Biopharma Inc | Equels Thomas K. | Exec. Vice COB, CEO, Pres | P - Purchase | $0.20 | +3,500 | 775,807 | 0% | +$711 | ||||||
| D | 2018-10-23 | LOGC | Logicbio Therapeutics, Inc. | Arix Bioscience Plc | 10% | P - Purchase | $10.00 | +700,000 | 2,979,023 | +31% | +$7,000,000 | |||||
| D | 2018-10-23 | LOGC | Logicbio Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $10.00 | +1,190,000 | 6,466,783 | +23% | +$11,900,000 | |||||
| D | 2018-10-23 | LOGC | Logicbio Therapeutics, Inc. | Kariv Tomer | Dir | P - Purchase | $10.00 | +420,000 | 1,787,413 | +31% | +$4,200,000 | |||||
| D | 2018-10-23 | LOGC | Logicbio Therapeutics, Inc. | Ioannidou Sofia | Dir | P - Purchase | $10.00 | +420,000 | 1,787,413 | +31% | +$4,200,000 | |||||
| D | 2018-10-23 | LOGC | Logicbio Therapeutics, Inc. | O'Connell Daniel P | Dir | P - Purchase | $10.00 | +700,000 | 2,979,023 | +31% | +$7,000,000 | |||||
| D | 2018-10-23 | LOGC | Logicbio Therapeutics, Inc. | Chimovits Erez | Dir | P - Purchase | $10.00 | +490,000 | 3,487,760 | +16% | +$4,900,000 | |||||
2018-10-25 | HEB | Hemispherx Biopharma Inc | Equels Thomas K. | Exec. Vice COB, CEO, Pres | P - Purchase | $0.20 | +100,000 | 772,307 | +15% | +$20,000 | ||||||
| M | 2018-10-22 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $33.95 | -7,800 | 776,363 | -1% | -$264,796 | |||||
| D | 2018-10-19 | BCRX | Biocryst Pharmaceuticals Inc | Staab Thomas R II | SVP, CFO | S - Sale+OE | $7.45 | -3,150 | 137,383 | -2% | -$23,468 | |||||
2018-10-19 | BCRX | Biocryst Pharmaceuticals Inc | Powell Lynne | SVP - CCO | S - Sale | $7.50 | -100 | 10,149 | -1% | -$750 | ||||||
2018-10-18 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | COO, 10% | P - Purchase | $20.00 | +25,000 | 4,150,086 | +1% | +$500,000 | ||||||
2018-10-18 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | P - Purchase | $20.00 | +25,000 | 4,150,086 | +1% | +$500,000 | ||||||
2018-10-19 | TTNP | Titan Pharmaceuticals Inc | Recli Federico Seghi | Dir | P - Purchase | $0.00 | +200,000 | 800,845 | +33% | +$0 | ||||||
2018-10-18 | EIGR | Eiger Biopharmaceuticals, Inc. | Interwest Partners X LP | 10% | S - Sale | $12.06 | -237,265 | 1,362,327 | -15% | -$2,862,321 | ||||||
| D | 2018-10-18 | RGNX | Regenxbio Inc. | Christmas Patrick J. | SVP, GC | S - Sale+OE | $61.78 | -5,000 | 17,669 | -22% | -$308,890 | |||||
| DM | 2018-10-17 | EDIT | Editas Medicine, Inc. | Myer Vickesh | CTO | S - Sale+OE | $29.20 | -7,000 | 0 | -100% | -$204,370 | |||||
| D | 2018-10-16 | RGNX | Regenxbio Inc. | Simpson Curran | SVP, Technical Operations | S - Sale+OE | $60.85 | -62,309 | 39,500 | -61% | -$3,791,503 | |||||
| D | 2018-10-15 | ALLO | Allogene Therapeutics, Inc. | Witte Owen N. | Dir | P - Purchase | $18.00 | +15,000 | 236,182 | +7% | +$270,000 | |||||
| D | 2018-10-15 | ALLO | Allogene Therapeutics, Inc. | Humer Franz B | Dir | P - Purchase | $18.00 | +30,000 | 104,870 | +40% | +$540,000 | |||||
| D | 2018-10-15 | ALLO | Allogene Therapeutics, Inc. | Chang David D | Pres, CEO | P - Purchase | $18.00 | +40,000 | 4,793,507 | +1% | +$720,000 | |||||
| D | 2018-10-15 | ALLO | Allogene Therapeutics, Inc. | Belldegrun Arie | Dir, 10% | P - Purchase | $18.00 | +35,000 | 2,020,586 | +2% | +$630,000 | |||||
| D | 2018-10-15 | ALLO | Allogene Therapeutics, Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | 10% | P - Purchase | $18.00 | +675,000 | 23,135,061 | +3% | +$12,150,000 | |||||
| DM | 2018-10-15 | RGNX | Regenxbio Inc. | Yoo Stephen | Chief Medical Officer | S - Sale+OE | $60.28 | -20,414 | 0 | -100% | -$1,230,541 | |||||
2018-10-15 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale | $59.37 | -7,500 | 137,283 | -5% | -$445,275 | ||||||
2018-10-15 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale | $59.35 | -7,510 | 326,000 | -2% | -$445,745 | ||||||
| D | 2018-10-15 | VCEL | Vericel Corp | Michel Gerard J | CFO, VP, Corp. Development | S - Sale+OE | $12.65 | -15,000 | 150,960 | -9% | -$189,750 | |||||
| D | 2018-10-15 | SGMO | Sangamo Therapeutics, Inc | Yi Kathy | SVP, CFO | S - Sale+OE | $13.97 | -5,000 | 7,250 | -41% | -$69,850 | |||||
2018-10-12 | BCDA | Biocardia, Inc. | McClung David | CFO | P - Purchase | $2.64 | +500 | 4,600 | +12% | +$1,318 | ||||||
| D | 2018-10-10 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $135.23 | -1,500 | 35,495 | -4% | -$202,839 | |||||
| M | 2018-10-10 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $16.98 | -143,576 | 6,542,153 | -2% | -$2,437,305 | |||||
2018-10-11 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.70 | +1,000 | 3,581,094 | 0% | +$2,700 | ||||||
| D | 2018-10-09 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $10.00 | +2,500,000 | 8,374,935 | +43% | +$25,000,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |